Ono Pharmaceutical (OTCMKTS:OPHLF) Sets New 52-Week Low at $15.96

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) reached a new 52-week low on Monday . The company traded as low as $15.96 and last traded at $15.96, with a volume of 1860 shares traded. The stock had previously closed at $15.96.

Ono Pharmaceutical Price Performance

The business has a 50 day moving average price of $16.48 and a two-hundred day moving average price of $17.24.

Ono Pharmaceutical (OTCMKTS:OPHLF) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.06. Ono Pharmaceutical had a return on equity of 16.32% and a net margin of 25.43%. The firm had revenue of $888.42 million during the quarter. On average, research analysts forecast that Ono Pharmaceutical Co., Ltd. will post 1.88 EPS for the current year.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.